GINA 2023 update – facts you need to know Review article
Article Sidebar
Main Article Content
Abstract
Asthma is characterized by chronic inflammation of the airways caused by the interaction between various cells, cellular components, and cytokines. Asthma management is an ongoing process that requires ongoing monitoring and risk reduction. The long-term goals of asthma management are to achieve good symptom control and to minimize the future risk of asthma-related remodeling and mortality, exacerbations, persistent airflow limitation, and treatment side effects. Asthma treatment should be based on cooperation between the doctor and the patient. Global Initiative for Asthma (GINA) recommendations are based on scientific research, their successive update gave rise to the issuance of new guidelines in 2023. The most important changes, modifications and updates include:
∙ precise formulation of terminology related to drugs used in asthma
∙ clarifying the course of action in asthma
∙ modification of treatment regimens in adults and adolescents > 12 years of age ad hoc use of ICS + SABA was included as Step 2
∙ consideration of environmental aspects when choosing an inhaler
∙ updated recommendation on the treatment of severe asthma
∙ presentation of a practical guide to managing asthma exacerbations
∙ finding that treatment based on the FeNO score did not result in fewer exacerbations
∙ emphasize the fact that the use of digital tools for compliance is effective
∙ update of the strategy of non-pharmacological management of asthma – recommendation to encourage patients with asthma to physical activity
∙ updating data on preventive vaccinations.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Generoso A, Oppenheimer J. Asthma/obstructive pulmonary disease overlap: update on definition, biomarkers, and therapeutics. Curr Opin Allergy Clin Immunol. 2020; 20(1): 43-7.
3. Gawlik R, Bochenek B, Dąbrowski A et al. Ocena kontroli astmy w praktyce lekarza POZ – dlaczego należy monitorować zużycie SABA? Lekarz POZ. 2021; 3: 134-9.
4. Global Strategy for Asthma Management and Prevention (2023 update) (access: 8.06.2023).
5. Global Strategy for Asthma Management and Prevention (2022 update) (access: 8.06.2023).
6. Turner S, Cotton S, Wood J et al. Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial. Lancet Respir Med. 2022; 10(6): 584-92.
7. Chan A, De Simoni A, Wileman V et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022; 6(6): CD013030.
8. Valkenborghs SR, Anderson SL, Scott HA et al. Exercise training programs improve cardiorespiratory and functional fitness in adults with asthma: a systematic review and meta-analysis. J Cardiopulm Rehabil Prev. 2022; 42: 423-33.
9. McLoughlin RF, Clark VL, Urroz PD et al. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Respir J. 2022; 60: 2200546.
10. Bandell A, Ambrose CS, Maniaci J et al. Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis. Expert Rev Vaccines. 2021; 20(6): 717-28.